A Phase I First|in|Human Study of ABBV|011

A Phase 1 first-in-human study evaluating ... - Scholars@Duke grant

A Phase 1 first-in-human study evaluating safety, pharmacokinetics and efficacy of ABBV-706 as monotherapy and in combination with budigalimab (ABBV-181), ...

SOLID TUMORS - AbbVie Science

... (ABBV-181). Clin Transl Sci. 2021;14:277–287. Italiano A, et al. First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with ...

A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule ...

A First-in-Human Phase 1 Study of ABBV-525, a Small-Molecule MALT1 Inhibitor, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma.

1660TiP - First-in-human study of ABBV-969, a dual ... - OncologyPRO

1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate ...

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation A...

ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human ...

ASCO 2024: AbbVie to Showcases Robust Solid Tumor Pipeline ...

Data from the dose-escalation and colorectal cancer (CRC) dose-expansion cohort of an ongoing first-in-human Phase 1 study (NCT05029882) of ABBV ...

Eftozanermin alfa (ABBV-621) monotherapy in patients with ...

Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study. PHASE I ...

Phase 1 study of pembrolizumab plus chemotherapy as first-line ...

KEYNOTE-011 (NCT01840579) is an open-label, multipart, phase 1 study that was conducted in a Japanese population. The safety and tolerability of pembrolizumab ...

Clinical Trial: NCT03639194 - My Cancer Genome

Official Title: A Phase I Study of ABBV-011 as a Single-Agent and in ... Up to approximately 5 years after the first participant receives first ...

Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small ...

A Phase 1 Multicenter Dose Escalation and Dose Expansion Study of Antibody-Drug Conjugate MYTX-011 in Subjects With Non-Small Cell Lung Cancer - KisMET-01 ...

A Phase I First-in-Human Study of ABBV-383, a B-Cell Maturation ...

PURPOSE : ABBV-383, a B-cell maturation antigen × CD3 T-cell engaging bispecific antibody, has demonstrated promising results in an ongoing first-in-human phase ...

A phase 1, open-label, dose-escalation trial of oral TSR-011 in ...

... study drug compliance during the first treatment cycle. Results ... Meanwhile, TSR-011 inhibited CYP3A4 and CYP2D6 in human liver ...

First-in-human phase I study of ABBV-085, an antibody–drug ...

ABBV-085 is a monomethyl auristatin-E antibody–drug conjugate that targets LRRC15 and showed antineoplastic efficacy in preclinical experiments.

First-in-Human Phase I Study of ABBV-838, an Antibody-Drug ...

ABBV-838 is an antibody-drug conjugate targeting a unique epitope of CD2 subset 1, a cell-surface glycoprotein expressed on multiple myeloma cells. This ...

clinical pharmacokinetics of abbv-400, a novel c-met-targeting ...

Herein, pharmacokinetic (PK) and immunogenicity results from this ongoing study are reported. Methods: NCT05029882 is an ongoing, Phase 1, first-in-human ...

A phase I first-in-human study of ABBV-383, a B-cell maturation ...

This trial describes outcomes with ABBV-383, an anti B-cell maturation antigen 3 CD3 bispecific monoclonal antibody in patients with relapsed/ ...

M19-345 A Phase 1 First-in Human, Multi-Center, Open Label Dose ...

M19-345 A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of ABBV ...

SC-011 - Drug Targets, Indications, Patents - Patsnap Synapse

A Phase I Study of ABBV-011 as a Single-Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Relapsed or Refractory Small Cell Lung Cancer.

A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell ...

Non-Hodgkin's Lymphoma, Phase I. A First-in-Human Study of ABBV-525 (MALT1 Inhibitor) in B-Cell Malignancies. Volunteers. Health Professionals ...

A first‐in‐human study of the novel immunology antibody–drug ...

Aims ABBV-3373, an immunology antibody–drug conjugate composed of adalimumab conjugated to a proprietary glucocorticoid receptor modulator ...